WS
TTNP

Wedbush Securities’s Titan Pharmaceuticals TTNP Stock Holding History

Wedbush Securities’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6
Closed -$22K – 944
2018
Q2 		$22K Buy
+6
New +$20.1K ﹤0.01% 862
2018
Q1 		– Sell
-4
Closed -$18K – 890
2017
Q4 		$18K Buy
+4
New +$24.9K ﹤0.01% 844

Other funds holding TTNP

CWM
Cornerstone Wealth Management St. Peters, Missouri $2B AUM 19.19% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedbush Securities's TTNP Position: Q3 2018 in Review

Wedbush Securities sold out of Titan Pharmaceuticals (TTNP) in Q3 2018, closing a stake of 6 shares — an estimated $22K sold.

Wedbush Securities first reported a position in TTNP in Q4 2017 and held it in 2 quarters. The position peaked at $22K in Q2 2018. 26 funds tracked by Wall St. Rank hold TTNP as of Q3 2018.

  • Wedbush Securities reported no remaining Titan Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Wedbush Securities sold 6 Titan Pharmaceuticals shares in Q3 2018, an estimated $22K.
  • Wedbush Securities first reported a position in Titan Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Wedbush Securities's Titan Pharmaceuticals position peaked at $22K in Q2 2018.
  • 26 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2018.

Based on Wedbush Securities's 13F filing for Q3 2018, filed 13 Nov 2018.